Skip to main content
News

BioTissue

BioTissue noted that with the company’s strong focus on the high-growth ocular business, BioTissue is looking for partners for its surgical, wound and ortho product lines, which it reports has $33MM+ in revenue with EBITDA breakeven targeted for 2025E. 2024 Annual CG MTDF